Margitta M Retz
Overview
Explore the profile of Margitta M Retz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
3436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Wit M, Retz M, Rodel C, Gschwend J
Dtsch Arztebl Int
. 2021 Mar;
118(Forthcoming).
PMID: 33759759
Background: In Germany, bladder carcinoma accounts for 3-4 % of all malignant tumors. New study findings in the fields of endoscopy, surgery, and systemic therapy have led to multimodal treatment...
2.
Perez-Gracia J, Loriot Y, Rosenberg J, Powles T, Necchi A, Hussain S, et al.
Eur Urol
. 2018 Dec;
75(3):e82-e83.
PMID: 30502102
No abstract available.
3.
Perez-Gracia J, Loriot Y, Rosenberg J, Powles T, Necchi A, Hussain S, et al.
Eur Urol
. 2017 Dec;
73(3):462-468.
PMID: 29273410
Background: Patients with metastatic urothelial carcinoma (mUC) who progress after platinum-based chemotherapy have had few treatment options and uniformly poor outcomes. Atezolizumab (anti-programmed death-ligand 1) was approved in the USA...
4.
Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U, et al.
Lancet
. 2017 Dec;
391(10122):748-757.
PMID: 29268948
Background: Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand...
5.
Balar A, Galsky M, Rosenberg J, Powles T, Petrylak D, Bellmunt J, et al.
Lancet
. 2016 Dec;
389(10064):67-76.
PMID: 27939400
Background: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand...
6.
Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A, et al.
Lancet
. 2016 Mar;
387(10031):1909-20.
PMID: 26952546
Background: Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab, an engineered humanised immunoglobulin G1 monoclonal antibody...
7.
Retz M, Sidhu S, Blaveri E, Kerr S, Dolganov G, Lehmann J, et al.
Int J Cancer
. 2004 Nov;
114(2):182-9.
PMID: 15540205
Transitional cell carcinoma of the urinary bladder remains life threatening due to the high occurrence of metastases. Emerging evidence suggests that chemokines and their receptors play a critical role in...